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1. Introduction 
The constellation of abnormalities caused by insulin deficiency is called diabetes mellitus. 
The cause of clinical diabetes is always a deficiency of the effect of insulin at the tissue level. 
Type I diabetes or insulin- dependent diabetes mellitus (IDDM), is due to insulin deficiency 
caused by autoimmune destruction of the B cell in the pancreatic islets, and it accounts for 3-
5 % of cases and usually presents in children. Type 2 diabetes, or non-insulin-dependent 
diabetes mellitus (NIDDM), is characterized by the dysregulation of insulin release from the 
B cells, along with insulin resistance in peripheral tissues such as skeletal muscle, brain, and 
liver. Type 2 diabetes usually presents in overweight or obese adults. 
The incidence of diabetes in the human population has reached epidemic proportions 
worldwide and it is increasing at the rapid rate.150 million people in 2000, which is 
predicted to rise to 220 million in 2010.  
In animals, it can be produced by pancreatectomy; by administration of alloxan, 
streptozocin, or other toxins that in appropriate doses cause selective destruction of the beta 
cells of the pancreatic islets; by administration of drugs that inhibit insulin secretion; and by 
administration of anti-insulin anti-bodies. Strains of mice, rats, hamsters, guinea pigs, 
miniature swine, and monkeys that have a high incidence of spontaneous diabetes mellitus 
have also been described.  
Diabetes is characterized by polyuria, polydipisa, weight loss in spite of polyphagia, 
hyperglycemia, glycosuria, ketosis, acidosis, and coma. Widespread biochemical 
abnormalities are present, but the fundamental defects to which most of the abnormalities 
can be traced are 1) reduced entry of glucose into various peripheral tissues and 2) increased 
liberation of glucose into the circulation from the liver. Therefore there is an extracellular 
glucose  excess and, in many cells, an intracellular glucose deficiency a situation that has 
been called starvation in the midst of plenty. Also, the entry of amino acids into muscle is 
decreased and lipolysis is increased.  
2. Diabetes complication 
Diabetic complications are divided to two parts: 1) metabolic complication and 2) vascular 
complication.  
2.1 Metabolic complication 
Obesity is increasing in incidence, and relates to the regulation of food intake and energy 
balance and overall nutrition. It is special relation to disordered carbohydrate metabolism 
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and diabetes. As body weight increase, insulin resistance increase, that is, there is a 
decreased ability of insulin to move glucose into fat and muscle and shut off glucose release 
from liver. The liver takes up glucose from the bloodstream and stores it as glycogen, but 
because the liver contains glucose 6- phosphates it also discharges glucose into the blood–
stream. Insulin facilitates glycogen synthesis and inhibits hepatic glucose output. When the 
plasma glucose is high, insulin secretion is normally increased and hepatic glucogenesis is 
decreased. This response dose not occurs in type I and II diabetes.  
When plasma glucose is episodically elevated over time, small amounts of hemoglobin A 
are nonenzymatically glycated to from HbA1c. Careful control of the quently HbA1c level is 
measured clinically as an integrated index of diabetic control for the 4 to 6 weeks period 
before the measurement. Many studies showed that the mean HbA1c value was a good 
predictor of ischemic heart disease. In particular, the multivariate analysis showed that per 
each 1% increment in HbA1c there was a 10% increase in the risk of coronary heart disease.  
Some studies believed that 1% reduction in HbA1c level led to a 16% reduction in the 
occurrence of myocardial infarction.  
Peripheral neuropathy, often expressed as hypersensitivity to painful stimuli, is among the 
most common complications of diabetes that develops in up to 60% of patients. It occurs in 
both type I and II diabetes and its incidence is linked to duration of disease. Neuropathic 
pain is a chronic or persistent pain characterized by alterations in pain perception, enhanced 
sensitivity to noxious stimuli (hyperalgesia) and abnormal pain sensitivity to previously 
non-painful stimuli (allodynia). Though the pathophysiology of neuropathy in diabetes has 
not been fully elucidated, hyperglycemia induced by diabetes is though to contribute to its 
development and maintaining good glycemic control could restrict the onset and 
progression of diabetic neuropathy.  
2.2 Vascular complication 
Hyperglycemia has a direct, harmful effect on the cardiovascular system requires, at the 
very least, a link between acute hyperglycemia and one or more risk factors for 
cardiovascular disease (CVD). Associated with obesity there is hyperinsulinemia, high 
circulating triglyceride and low HDL, and accelerated development of atherosclerosis. In 
diabetes, the plasma cholesterol level is usually elevated and this plays a role in the 
accelerated development of the atherosclerotic vascular disease that is a major long-term 
complication of diabetes in humans. 
As usual diabetes is characterized by a high incidence of CVD, and poor control of 
hyperglycemia appears to play a significant role in the development of CVD in diabetes. 
Recently, there has been increasing evidence that the postprandial state is an important 
contributing factor to the development of atherosclerosis. In diabetes the postprandial phase 
is characterized by a rapid and large increase in blood glucose levels, and the possibility that 
these postprandial hyperglycemic spikes may be relevant to the pathophysiology of the late 
diabetes complications. 
Insulin resistance (IR) has profound, negative effects on the function of arteries and 
arterioles throughout the body. In addition to the obvious link between IR and the 
development of type 2 diabetes, IR-associated dysfunction of resistance vessels is associated 
with arterial hypertension and vascular occlusive diseases. IR affects arteries and arterioles 
at both the endothelium and smooth muscle levels. For example, IR causes reduced 
responsiveness of vascular smooth muscle to dilator agents; predominantly due to impaired 
potassium channel function. 
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Vascular disease is one of the complicating features of diabetes mellitus. Several prospective 
studies have indicated that hypertension in diabetic patient’s takes place at a rate more than 
twice compared to the normal population. The hypertension is also considered an 
independent risk factor for cardiovascular mortality in patients with diabetes. It has been 
suggested that alterations in the reactivity of blood vessels to neurotransmitters and 
circulating hormones are responsible for the cardiovascular complications of diabetes.  Some 
studies showed that Ca/Mg ratio is a marker of vascular tone; its increase represents 
increased vascular reactivity and atherogenic risk. Atherogenic lesion is poorly correlated 
with serum cholesterol level and is highly dependent on plasma magnesium level and 
Ca/Mg ratio. Pervious studies showed that Ca/Mg ratio increase in diabetic case. 
Endothelial function is altered early in diabetes. It has been demonstrated that in diabetic 
subjects, the vasodilating response to stimuli is diminished and that this anomaly is related 
to glycemic control. In vivo studies have demonstrated that hyperglycemic spikes induce, in 
both diabetic and normal subjects, an endothelial dysfunction. This effect of hyperglycemia 
is probably linked with a reduced production/bioavailability of nitric oxide (NO), since 
hyperglycemia-induced endothelial dysfunction is counterbalanced by arginine. 
Furthermore, it is very interesting that a rapid decrease of flow-mediated vasodilation has 
been shown in the postprandial phase in type II diabetes patients and that the decrease 
correlated inversely with the magnitude of postprandial hyperglycemia.  
3. Prevention of diabetes complications 
Type I diabetes usually develops before the age 40, patients with this disease are not obese 
and they have a high incidence of ketosis and acidosis. Various anti-B cell antibodies are 
present in plasma, but the current thinking is that type I diabetes is primarily a T 
lymphocyte-mediated disease. But type II diabetes is the most common type of diabetes and 
is usually associated with obesity. It usually develops after age 40 and is not associated with 
total loss of the ability to secrete insulin. It has an insidious onset, is rarely associated with 
ketosis, and is usually associated with normal beta-cells morphology and insulin content if 
the beta-cells have not become exhausted. So it seems we should look for different methods 
for prevention of type I and II diabetes. 
3.1 Diabetes diet 
Several lifestyle factors affect the incidence of type 2 diabetes. Obesity and weight gain 
dramatically increase the risk, and physical inactivity further elevates the risk, independently 
of obesity. Cigarette smoking is associated with a small increase and moderate alcohol 
consumption with a decrease in the risk of diabetes. In addition, a low-fiber diet with a high 
glycemic index has been associated with an increased risk of diabetes, and specific dietary 
fatty acids may differentially affect insulin resistance and the risk of diabetes. 
Excess body fat is the single most important determinant of type II diabetes. Weight control 
would be the most effective way to reduce the risk of type II diabetes, but current strategies 
have not been very successful on a population basis, and the prevalence of obesity continues 
to increase. The public generally does not recognize the connection between overweight or 
obesity and diabetes. Thus, greater efforts at education are needed. 
Low-fat vegetarian and vegan diets are associated with reduced body weight, increased 
insulin sensitivity, and reductions in cardiovascular risk factors. The potential 
cardiovascular benefits of vegetarian and vegan diets may be especially important for 
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individuals with diabetes, for whom cardiovascular disease is a main cause of premature 
mortality; the effects of such diets on cardiovascular risk factors appear to be similar in 
individuals with and without diabetes.  
Prior studies have shown that near-vegetarian diets reduce the need for insulin and oral 
medications in individuals with type 2 diabetes. We previously reported that in individuals 
with type 2 diabetes, a low-fat, vegan diet was associated with improved glycemic control, 
weight loss, and improved plasma lipid control during a 22-wk study period. What is 
particularly critical in diabetes management is long-term improvement in clinical measures, 
particularly glycemia and cardiovascular risk factors. Well-planned low-fat vegan diets are 
nutritionally adequate and, in research studies, have shown acceptability comparable with 
that of other therapeutic diets, suggesting they are suitable for long-term use.  
3.2 Immunosupression drug 
If type one diabetic patient give immunosupression drugs like cyclosporine ameliorate 
early in the disease, before all beta cells are lost can be useful for prevention of disease. 
But chose the low fat and low carbohydrate diets could be useful for prevention of type 2 
diabetes. 
4. Magnesium 
Some studies indicated that magnesium is a novel factor implicated in the pathogenesis of 
the complication of diabetes. Magnesium plays a fundamental role as a cofactor in various 
enzymatic reactions of energy metabolism. Magnesium is a cofactor in cell membrane 
glucose-transporting mechanisms, as well as in various enzymes in carbohydrate oxidation.  
It is also involved, at multiple levels, in insulin secretion, binding and activity. Magnesium 
deficit has been described in patients with type I diabetes. Hypomagnesemia can also be the 
cause or a result of diabetes complications. If it is followed by diabetes, osmotic diuresis 
may play a role in the mechanisms responsible for magnesium deficiency. Magnesium loss 
may be linked to the development of diabetes complications via a reduction in the rate of 
inositol transport and its subsequent intracellular depletion that might enhance the 
development of complications. Studies showed that the administration of magnesium 
corrected hyperglycemia and has brought blood glucose back to normal levels within 24 h of 
its administration. Moreover, magnesium appears to have some reparative effect on the 
pancrease of diabetic case. Accordingly, during long-term treatment, pancreatic repair may 
have an effective role in the control of plasma glucose levels. Magnesium also is a necessary 
cofactor for many enzymes which is involved in lipid metabolism. Mg-deficiency enhances 
catecholamine secretion which result in an increase in lipolysis and blood plasma 
magnesium has been shown to decrease when lipolysis is increased. Enhancement in 
lipolysis and subsequent elevation of plasma free fatty acids levels may lead to an increase 
in hepatic VLDL and triglycerides synthesis and secretion and elevated plasma triglyceride 
concentration. The hepato-biliary pathway is the main rout for removal of cholesterol from 
the body. Bile flow is significantly lower in Mg-deficient subject than in controls and the 
cholesterol concentration in bile is decreased. Magnesium administration could decrease 
triglycerides, cholesterol and LDL cholesterol and also increased HDL cholesterol. The 
decrease in serum triglycerides was associated with the change in serum total Mg 
concentration. Other supporting evidence is accumulating for the role of magnesium in the 
modulation of serum lipids and lipids uptake in macrophages. Studies showed that increase 
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in plasma endothelin I due to magnesium deficiency and a direct effect of magnesium 
deficiency on vascular smooth muscle are involved in the elevation of vascular tone in 
diabetic pateint. Elevated vascular tone can contribute to increased blood pressure. Some 
studies have observed that systolic and diastolic blood pressure and mean arterial blood 
pressure in Mg-treated chronic diabetic subject are lower than in chronic diabetic. The 
administration of magnesium can decrease vascular bed sensitivity to phenylephrine and 
decrease Ca/Mg ratio. Studies also showed that magnesium decreases collagen thickness, 
intima/media thickness and the lumen/ media ratio in aorta.  This suggests that the 
administration of magnesium can decrease blood pressure and prevent vascular 
morphological changes and decrease in vascular sensitivity to neurotransmitter. 
Hemoglobin deficiency is observed in diabetic subjects. This can probably be explained by 
the inhibition of ð-aminolevulinate dehydratase (ð-ALA-D) in diabetes. Studies have found 
that this enzyme is inhibited by glycation of the active site lysine residue involved in Schiff’s 
base formation with the first ð-ALA-D molecule. Magnesium administration reduces this 
glycation via blood glucose reduction and, thus, prevents hemoglobin deficiency. So it 
seems that magnesium administration may play in the management of diabetes and the 
prevention of its vascular complications in diabetic patients. 
5. Glucagone-like peptide-1 (GLP-1) 
Type I diabetes is a complex disease that results from an autoimmune T-lymphocyte-
dependent islet infiltration and destruction of islet beta- cells, with consequent insulin 
deficiency and dependence on exogenous insulin treatment. A strikingly decreased 
functional beta- cell mass owing to apoptosis constitutes the histopathological hallmark of 
the disease at diagnosis. Recently, strategies employing beta-cell growth factors to enhance 
functional beta-cell mass and restore insulin secretion have been proposed for the treatment 
and prevention of diabetes. One such promising beta-cell growth factor identified is 
glucagone-like peptide-1 (GLP-1). GLP-1 is an insulinotropic hormone that is secreted from 
intestinal L-cell in response to nutrient ingestion and promotes nutrient absorption via 
regulation of islet hormone secretion. GLP-1 receptor is expressed mainly by pancreatic 
beta-cells, and to some extent in other tissues like lung, kidney and brain. GLP-1 enhances 
pancreatic islet beta-cell proliferation and inhibits beta-cell apoptosis in a glucose-dependent 
fashion. Other actions of GLP-1 are to decrease glucagons secretion and gastric emptying. 
Together, all these actions tend to lower the plasma glucose concentration and to limit 
plasma glucose rises with meals. GLP-1 is another gastrointestinal hormone that is also 
expressed in the hypothalamus and brainstem. Their CNS actions are to decrease food 
intake, decrease water intake, and increase diuresis. However, native GLP-1 has a short 
circulating half-life (less than 2 min) that results mainly from rapid enzymatic inactivation 
by dipeptidyl-peptidase IV (DPP- IV), and/ or renal clearance. Therefore, continuous 
subcutaneous infusion by pump is necessary to maintain GLP-1 action. DPP- IV-resistant 
GLP-1 analogues and other formulations appear to be promising therapeutic drug 
candidates for the treatment and prevention of diabetes, but these peptides require once or 
twice-daily injections and/or combination therapies with oral diabetic medications. 
Scientifics recently developed a novel GLP-1 fusion peptide consisting of the active human 
GLP-1 molecule and the murine IgG1 constant heavy-chain (IgG-Fc). Plasmid-based, 
electroporation-enhanced intramuscular gene therapy with GLP-1/IgG-Fc improved insulin 
production and normalized glucose tolerance in type one or two diabetes. 
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6. Gama amino butyric acid (GABA) 
Gama amino butyric acid (GABA) is an important neurotransmitter which was initially 
identified in the central nervous system and is also found in islet beta-cells. GABA has an 
important role in pathogenesis of diabetes. Excessive secretion of glucagon is a major 
contributor to the development of diabetic hyperglycemia. Secretion of glucagon is 
regulated by various nutrients, with glucose being a primary determinant of the rate of 
alpha-cell glucagon secretion. The intra-islet action of insulin is essential to exert of 
insulin, glucose is not able to suppress glucagons release in vivo. However, the precise 
mechanism by which insulin suppresses glucagon secretion from alpha-cells is unknown. 
Studies showed that insulin induces activation of GABAA Akt kinase-dependent 
pathway. This leads to membrane hyperpolarization in the alpha-cells and, ultimately, 
suppression of glucagon secretion. Researchers propose that defects in this pathway 
contribute to diabetic hyperglycemia. It is well known that the secretion of glucagon is 
abnormal in human type I diabetes patients. The patients do not secrete glucagon in 
response to hypoglycemia and they have an exaggerated response of glucagon to stimuli 
such as arginine infusion and a protein meal. In studies of patients with type I diabetes 
there are indications of an increase in alpha cell numbers. GABA decreases in diabetic 
patients. Some studies indicated that a reduction in cellular GABA level is more sensitive 
than insulin as a marker for the presence of dead beta-cells in isolated preparations. 
Pancreatic GABA content also rapidly decreased after diabetes induction and remained 
unaffected by 12 h of hyperglycemia. It seems that GABA therapy can has some beneficial 
effect to prevention or treatment type I diabetes.  
7. Antioxidants 
Increasing evidence in both experimental and clinical studies suggests that oxidative stress 
play a major role in the pathogenesis of both types of diabetes mellitus. Diabetes is usually 
accompanied by increased production of free radicals or impaired antioxidant defenses. 
Mechanisms by which increased oxidative stress is involved in the diabetic complication are 
partly known, including activation of transcription factors, advanced glycated end products 
(AGEs), and protein kinase C.  
Excessively high levels of tree radicals cause damage to cellular proteins, membrane lipids 
and nucleic acids, and eventually cell death. Various mechanisms have been suggested to 
contribute to the formation of these reactive oxygen-free radicals. Glucose oxidation is 
believed to be the main source of free radicals. In its enediol form, glucose is oxidized in a 
transition-metal-dependent reaction to an enddiol radical anion that is converted into 
reactive ketoaldehydes and to superoxide anion radicals. The superoxide anion radicals 
undergo dismutation to hydrogen peroxide, which if not degraded by catalase or 
glutathione peroxidase, and in the presence of transition metals, can lead to production of 
extremely reactive hydroxyl radicals. Superoxide anion radicals can also react with nitric 
oxide to form reactive peroxynitrite radicals. Hyperglycemia is also found to promote lipid 
peroxidation of LDL by a superoxide- dependent pathway resulting in the generation of free 
radicals. Another important source of free radicals in diabetes is the interaction of glucose 
with proteins leading to the formation of Amadori product and then advanced glycation 
endproducts (AGEs). These AGEs, via their receptors (RAGEs), inactivate enzymes and alter 
their structures and functions, promote free radical formation, and quench and block 
www.intechopen.com
 Prevention of Diabetes Complications   
 
359 
antiproliferative effects of nitric oxide. By increasing intracellular oxidative stress, AGEs 
activate the transcription factor NF-kB, thus promoting up-regulation of various NF-kB 
controlled target genes. NF-kB enhances production of nitric oxide, which is believed to be a 
mediator of islet beta cell damage. 
Considerable evidence also implicates activation of the sorbitol pathway by glucose as a 
component in the pathogenesis of diabetic complications, for example, in lens cataract 
formation or peripheral neuropathy. Efforts to understand cataract formation have 
provoked various hypotheses. In the aldose reductase osmotic hypothesis, accumulation of 
polyols initiates lenticular osmotic changes. In addition, oxidative stress is linked to 
decreased glutathione levels and depletion of NADPH levels. Alternatively, increased 
sorbitol dehydrogenase activity is associated with altered NAD+ levels, which results in 
protein modification by nonenzymatic glycosylation of lens proteins. 
Mechanisms linking the changes in diabetic neuropathy and induced sorbitol pathway are 
not well delineated. One possible mechanism, metabolic imbalances in the neural tissues, 
has been implicated in impaired neurotrophism, neurotrsnsmission changes, Schwann cell 
injury, and axonopathy. 
While on the one hand hyperglycemia engenders free radicals, on the other hand it also 
impairs the endogenous antioxidant defense system in many ways during diabetes. 
Antioxidant defense mechanism involves both enzymatic and nonenzymatic strategies. 
Common antioxidants include the vitamins A, C and E, antioxidant minerals (copper, zinc, 
manganese, and selenium), and the cofactors (folic acid, vitamins B1, B2, B6, B12). They 
work in synergy with each other and against different types of free radicals. Vitamin E 
suppresses the propagation of lipid peroxidation; vitamin C with vitamin E inhibits 
hydroperoxide formation; metal complexing agents, such as penicillamine, bind transition 
metal involved in some reactions in lipid peroxidation and inhibit Fenton and Haber-weiss-
type reactions; vitamins A and E scavenge free radicals. 
8. Herbal medicine 
Recently, the search for appropriate hypoglycemic agents has been focused on plants.  Many 
herbal medicines have been recommended for the treatment of diabetes. Plant drugs are 
frequently considered to be less toxic and free from side effect than synthetic ones. The leaf 
of Psidium guava, Teucrium polium, Cinnamon and Garlic are used traditionally in many 
countries to manage, control and treat of diabetes. Some recent studies have shown that 
administration of Psidium guava or Teucrium polium leaves decrease blood glucose via 
enhance insulin secretion.  
Psidium guajva Linn., commonly known as guava, is a native plant in tropical American 
and has long been naturalized in south east Asia and in south of Iran. Different parts of the 
plant are used in traditional medicine for the treatment of various human aliments such as 
wound, ulcers, bronchitis, cyesores and diarrhea. In folklore guava has been used for a long 
time as a medicinal herb to cure diabetes mellitus. Many people in some countries including 
Japan, Taiwan and Iran boil guava leaves in water and drink the exact as a folk medicine for 
diabetes and hypertension. Psidium guajava leaves have a beneficial effects on diabetes 
metabolic syndrome and vascular complications.  
Photochemical analysis of Psidium guajava leaves have revealed the presence of flavonoids, 
which include quercetin and its derivatives (guajaverin, isoquercitrin, hyperin, quercitrin, 
avicularin), morin and its derivatives (morin-3-O-┙-L-lixopyranoside and morin-3-O-┙-L-
www.intechopen.com
  
Type 1 Diabetes Complications 
 
360 
arabopyranoside), rutin, myricetin, luteolin and kaempferol. The leaves of the plant have 
also been shown to contain essential oil, fixed oil, volatile oil, saponin, resin, tannin, 
triterpenoids, asiatic acid and ellagic acid.  
The relaxant effect of Psidium guajva Linn., on endothelium-intact aortic rings were only 
partially inhibited by N-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase 
inhibitor, suggesting that the vasorelaxant effect of Psidium guajva Linn., on aortic rings is 
probably mediated via both endothelium-derived relaxing factor (EDRF)-dependent and 
EDRF-independent mechanisms but it seems this mechanism is not follow in diabetic rat 
vessel.  
Teucrium polium L. is one of 300 species of the genus Teucrium and found mainly in the 
Mediterranean and Western Irano-Turanian sphere. It is widely distributed in Iran, Jordan 
and Palestine. The leaves 1-3 cm long, are sessile, oblong or linear, the stems are ending in a 
shortly paniculate or corymbose infoflorescences, corolla is white or pale cream colored. 
Several researchers have evaluated Teucrium polium grown in different geographic origin 
and it has flavonoids and iridoids. Hypoglycemic activity has been reported - in addition to 
the flavonoids- also for the volatile oils. Traditionally, especially in the Mediterranean 
countries and in Iran, Teucrium polium, is used for its antispasmodic and hypoglycemic 
activities by the native inhabitants and recommended by the herbalists. Anti-inflammatory, 
anti-hypertensive, antinociceptive, anti-ulcer and anorexic effects are other activities 
reported. Some investigators have reported reduction in blood glucose concentrations of 
animal diabetic model after treatment with a single i.v., i.p. and oral dose of Teucrium 
polium aqueous decoction. Some Iranian researchers have observed significant decrease in 
blood glucose in animal diabetic model after six weeks of consecutive oral treatment with 
ethanol/ water extract.  
Spices such as Cinnamon display insulin-enhancing activity in vitro. Cinnamon can 
improve glucose metabolism and the overall condition of individuals with diabetes not 
only by hypoglycemic effects but also by improving lipid metabolism, antioxidant status, 
and capillary function. Aqueous extracts from Cinnamon have also been shown to 
increase in vitro glucose uptake and glycogen synthesis and to increase phosphorylation 
of the insulin receptor; in addition, these Cinnamon extracts are likely to aid in triggering 
the insulin cascade system. Because insulin also plays a key role in lipid metabolism, 
consumption of Cinnamon would lead to improved glucose and blood lipids in vitro. The 
mechanism of the effect of Cinnamon on glucose and blood lipids is not completely 
understood but the researchers believe that extracts of Cinnamon activated glycogen 
synthase, increased glucose uptake, and inhibited glycogen synthase kinase-3┚. Extracts 
of Cinnamon also activated insulin receptor kinse and inhibited dephosphorylation of the 
insulin receptor, leading to maximal phosphorylation of the insulin receptor. All of these 
effects would lead to increased insulin sensitivity. The extract of Cinnamon also has 
function as potent antioxidants, which would lead to additional health benefits of this 
substance. 
Garlic was known to be effective in decreasing, cholesterol and can inhibit LDL-Oxidation. 
Many clinical trials have been conducted to determine the lipid-lowering effects of fresh 
garlic and garlic supplements. Garlic consumption also can decrease blood glucose in 
diabetic patients and has beneficial effect on diabetic vessel.  It seems that daily Garlic 
consumption can be useful to prevent of diabetes.   
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